<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="pmc-domain-id">3416</journal-id><journal-id journal-id-type="pmc-domain">molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430443</article-id><article-id pub-id-type="pmcid-ver">PMC12430443.1</article-id><article-id pub-id-type="pmcaid">12430443</article-id><article-id pub-id-type="pmcaiid">12430443</article-id><article-id pub-id-type="doi">10.3390/molecules30173584</article-id><article-id pub-id-type="publisher-id">molecules-30-03584</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Discovery of Novel Benzamide-Based Sigma-1 Receptor Agonists with Enhanced Selectivity and Safety</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8893-5155</contrib-id><name name-style="western"><surname>Carato</surname><given-names initials="P">Pascal</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-molecules-30-03584" ref-type="aff">1</xref><xref rid="fn1-molecules-30-03584" ref-type="author-notes">&#8224;</xref><xref rid="fn2-molecules-30-03584" ref-type="author-notes">&#8225;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1199-7155</contrib-id><name name-style="western"><surname>Oxombre</surname><given-names initials="B">B&#233;n&#233;dicte</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-molecules-30-03584" ref-type="aff">1</xref><xref rid="fn1-molecules-30-03584" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ravez</surname><given-names initials="S">S&#233;verine</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-molecules-30-03584" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boulahjar</surname><given-names initials="R">Rajaa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-molecules-30-03584" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Donnier-Mar&#233;chal</surname><given-names initials="M">Marion</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-molecules-30-03584" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0028-1626</contrib-id><name name-style="western"><surname>Barczyk</surname><given-names initials="A">Am&#233;lie</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af2-molecules-30-03584" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liberelle</surname><given-names initials="M">Maxime</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><xref rid="af1-molecules-30-03584" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0997-8817</contrib-id><name name-style="western"><surname>Vermersch</surname><given-names initials="P">Patrick</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-molecules-30-03584" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9555-3446</contrib-id><name name-style="western"><surname>Melnyk</surname><given-names initials="P">Patricia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-molecules-30-03584" ref-type="aff">1</xref><xref rid="c1-molecules-30-03584" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Mork&#363;nien&#279;</surname><given-names initials="R">Ramun&#279;</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Kopustinskiene</surname><given-names initials="DM">Dalia M.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-30-03584"><label>1</label>Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience &amp; Cognition, F-59000 Lille, France; <email>pascal.carato@univ-poitiers.fr</email> (P.C.); <email>benedicte.vanteghem@univ-lille.fr</email> (B.O.); <email>severine.ravez@univ-lille.fr</email> (S.R.); <email>maxime.liberelle@univ-lille.fr</email> (M.L.); <email>patrick.vermersch@univ-lille.fr</email> (P.V.)</aff><aff id="af2-molecules-30-03584"><label>2</label>Univ. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France; <email>amelie.barczyk@univ-lille.fr</email></aff><author-notes><corresp id="c1-molecules-30-03584"><label>*</label>Correspondence: <email>patricia.melnyk@univ-lille.fr</email></corresp><fn id="fn1-molecules-30-03584"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn><fn id="fn2-molecules-30-03584"><label>&#8225;</label><p>Current address: Univ. Poitiers, CIC INSERM 1402, EBI UMR CNRS 7267, F-86073 Poitiers, France.</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>30</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496502</issue-id><elocation-id>3584</elocation-id><history><date date-type="received"><day>09</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>29</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 16:25:51.440"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="molecules-30-03584.pdf"/><abstract><p>Central nervous system (CNS) disorders such as neurodegenerative diseases, multiple sclerosis, or even brain ischemia represent major therapeutic challenges with limited effective treatments. The sigma-1 receptor (S1R), a unique ligand-operated molecular chaperone enriched at mitochondria-associated membranes, has emerged as a promising drug target due to its role in neuroprotection and neuroinflammation. Building upon our previously identified S1R ligand (compound <bold>1</bold>), we designed and synthesized six novel benzamide derivatives through pharmacomodulation to optimize affinity, selectivity, and safety profiles. Among these, compound <bold>2</bold> demonstrated superior S1R affinity, improved selectivity over the sigma-2 receptor (S2R), and favorable ADME properties, including enhanced permeability and markedly reduced in vitro cardiac toxicity compared to the lead compound. Functional assays confirmed the agonist activity of key derivatives, while safety evaluations revealed low cytotoxicity and minimal off-target receptor interactions. Collectively, these findings support compound <bold>2</bold> as a promising candidate for further preclinical development in S1R-related CNS disorders.</p></abstract><kwd-group><kwd>Sigma-1 receptor</kwd><kwd>central nervous system (CNS)</kwd><kwd>benzamide derivatives</kwd><kwd>pharmacomodulation</kwd><kwd>ADME</kwd><kwd>drug discovery</kwd></kwd-group><funding-group><award-group><funding-source>University of Lille, Inserm, and Genzyme Sanofi</funding-source></award-group><funding-statement>This research was funded by the University of Lille, Inserm, and Genzyme Sanofi. Marion Donnier-Mar&#233;chal was the recipient of a fellowship from the University of Lille.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-30-03584"><title>1. Introduction</title><p>Neurodegenerative diseases and ischemic stroke represent major health challenges of the 21st century, contributing to rising morbidity and mortality through progressive physical and cognitive decline. A key pathological hallmark shared by these conditions is the disruption of mitochondria-endoplasmic reticulum (ER) communication [<xref rid="B1-molecules-30-03584" ref-type="bibr">1</xref>,<xref rid="B2-molecules-30-03584" ref-type="bibr">2</xref>]. This specialized subcellular interface, known as the mitochondria-associated membrane (MAM), plays a central role in maintaining cellular homeostasis and is critically involved in diverse biological processes, including calcium signaling, lipid metabolism, inflammation, autophagy, apoptosis, and ER stress responses [<xref rid="B3-molecules-30-03584" ref-type="bibr">3</xref>].</p><p>The MAM harbors a variety of functional proteins, among which the sigma-1 receptor (S1R) has attracted increasing interest over the past decade due to its emerging role in brain disorders [<xref rid="B4-molecules-30-03584" ref-type="bibr">4</xref>,<xref rid="B5-molecules-30-03584" ref-type="bibr">5</xref>,<xref rid="B6-molecules-30-03584" ref-type="bibr">6</xref>]. S1R is a highly conserved and dynamic protein expressed across species and cell types. Although present in the ER, nuclear, and plasma membranes, it is particularly enriched at the MAM. In the central nervous system (CNS), S1R is widely expressed in both neurons and glial cells, where it modulates key physiological functions such as neuroprotection, neuroinflammation, neurotransmission, and neuroplasticity.</p><p>Unlike classical receptors, S1R does not conform to standard pharmacological paradigms: its endogenous ligand remains elusive, and no canonical signal transduction cascade has been identified. Instead, S1R functions as a unique, ligand-operated molecular chaperone. Upon specific activation, S1R translocates to multiple subcellular compartments&#8212;including the ER, nuclear, mitochondrial, and plasma membranes, as well as cytosolic vesicles and even the extracellular milieu&#8212;where it modulates the activity of various receptors, ion channels, transporters, and enzymes, either enhancing or attenuating their signaling.</p><p>Given its multifaceted role, S1R has emerged as a promising therapeutic target. Several small molecules with favorable pharmacokinetic and pharmacodynamic properties have been developed, both as potential drugs and as molecular imaging tracers [<xref rid="B7-molecules-30-03584" ref-type="bibr">7</xref>]. For instance, blarcamesine (Anavex 2-73), a compound targeting S1R and muscarinic receptors, has successfully completed Phase 2/3 clinical trials for Rett syndrome and early-stage Alzheimer&#8217;s disease (AD) [<xref rid="B8-molecules-30-03584" ref-type="bibr">8</xref>,<xref rid="B9-molecules-30-03584" ref-type="bibr">9</xref>]. Pridopidine, which targets S1R and dopamine D2/D3 receptors, has undergone Phase 2 evaluation for levodopa-induced dyskinesia and Phase 3 trials for early Huntington&#8217;s disease (HD) [<xref rid="B10-molecules-30-03584" ref-type="bibr">10</xref>,<xref rid="B11-molecules-30-03584" ref-type="bibr">11</xref>].</p><p>Our team previously identified the tetrahydroisoquinoline-hydantoin scaffold as a key pharmacophore for S1R modulation [<xref rid="B12-molecules-30-03584" ref-type="bibr">12</xref>]. Compounds selected based on their S1R agonist profiles have demonstrated promising potential in preclinical models of central nervous system (CNS) disorders, including brain ischemia, multiple sclerosis (MS), and cocaine addiction [<xref rid="B13-molecules-30-03584" ref-type="bibr">13</xref>,<xref rid="B14-molecules-30-03584" ref-type="bibr">14</xref>]. Through pharmacomodulation efforts, we synthesized several series of compounds featuring benzannulated motifs, tricyclic heterocycles, and benzamide scaffolds, all exhibiting high affinity for S1R [<xref rid="B15-molecules-30-03584" ref-type="bibr">15</xref>]. These compounds typically consist of a heterocyclic core linked to a benzylmethylamine moiety via aliphatic chains of two, three, or four methylene units. Among the various series, the simple benzamide derivatives stood out for their improved metabolic stability, excellent S1R-binding affinity, high selectivity, and lack of in vitro cytotoxicity [<xref rid="B15-molecules-30-03584" ref-type="bibr">15</xref>]. Comprehensive evaluation of absorption, distribution, metabolism, and excretion (ADME) properties, along with safety pharmacology and toxicology studies, was conducted using standardized in vitro and in vivo methodologies. These assessments confirmed favorable drug-like characteristics, including the potential for oral administration, supporting their development as selective and safe S1R-targeted therapeutic candidates [<xref rid="B16-molecules-30-03584" ref-type="bibr">16</xref>].</p><p>Building on these promising findings, further development of next-generation S1R ligands is warranted to enhance efficacy, selectivity, and drug-like properties. Starting from the previously identified benzamide scaffold and its most potent derivative (compound <bold>1</bold>), we designed a new series of analogs by inverting the amide bond while maintaining the distance between the two phenyl rings (<xref rid="molecules-30-03584-f001" ref-type="fig">Figure 1</xref>). Structural variations were introduced by modulating both the position and the nature of the substituent (R group), incorporating halogen atoms (Cl, Br) as well as electron-withdrawing groups such as cyano and nitro moieties (compounds <bold>2</bold>&#8211;<bold>7</bold>).</p></sec><sec sec-type="results" id="sec2-molecules-30-03584"><title>2. Results and Discussion</title><sec id="sec2dot1-molecules-30-03584"><title>2.1. Chemistry</title><p>Starting from the commercial substituted <italic toggle="yes">N</italic>-benzylamine (<bold>8a</bold>&#8211;<bold>f</bold>), reaction in dichloromethane with 4-chloropropionyl chloride gave the corresponding compounds <bold>9a</bold>&#8211;<bold>f</bold>. These derivatives <bold>9a</bold>&#8211;<bold>f</bold> were engaged in benzylmethylamine, which reacted both as a base and a solvent, and afforded the final compounds <bold>2</bold>&#8211;<bold>7</bold> (<xref rid="molecules-30-03584-sch001" ref-type="fig">Scheme 1</xref>, <xref rid="app1-molecules-30-03584" ref-type="app">Figure S1</xref>).</p></sec><sec id="sec2dot2-molecules-30-03584"><title>2.2. Biological Evaluation and SAR</title><p>S1R and S2R affinities were classically evaluated through competitive binding assays using radioligands, following the protocol described by Ganapathy et al. [<xref rid="B17-molecules-30-03584" ref-type="bibr">17</xref>]. The selective radioligand [<sup>3</sup>H] (+)-pentazocine was employed as the classic prototypical ligand, selectively binding to the orthosteric S1R-binding sites. [<sup>3</sup>H]-DTG was used as the most useful radioligand to study compounds classified as S2R ligands, in the presence of an excess of unlabeled (+)-pentazocine to selectively block S1R. Jurkat cell membranes served as the receptor source in both assays. The equilibrium dissociation constants (<italic toggle="yes">K</italic>i) for S1R and S2R were derived from the IC<sub>50</sub> values of each compound, and selectivity ratios (S2R/S1R) were subsequently calculated (<xref rid="molecules-30-03584-t001" ref-type="table">Table 1</xref>, <xref rid="app1-molecules-30-03584" ref-type="app">Figures S2 and S3</xref>).</p><p>The lead compound <bold>1</bold> exhibited high affinity for S1R (<italic toggle="yes">K</italic>i = 3.2 nM), with a selectivity ratio of 190. Substitution with a chloro atom at the <italic toggle="yes">para</italic> position (compound <bold>3</bold>) improved the S1R affinity (<italic toggle="yes">K</italic>i = 1.7 nM) and selectivity (S2R/S1R = 241). The highest S1R affinity (<italic toggle="yes">K</italic>i = 0.6 nM) was achieved with a chloro substituent at the <italic toggle="yes">meta</italic> position (compound <bold>2</bold>), displaying excellent selectivity (S2R/S1R = 317). In contrast, introducing a bulkier bromo atom at the <italic toggle="yes">meta</italic> position (compound <bold>4</bold>) drastically reduced the S1R affinity (<italic toggle="yes">K</italic>i &gt; 200 nM). The dichloro-substituted derivative <bold>5</bold> maintained good S1R affinity (<italic toggle="yes">K</italic>i = 2.3 nM) but showed reduced selectivity (S2R/S1R = 52). Electron-withdrawing cyano substitution (compound <bold>6</bold>) preserved good S1R affinity (<italic toggle="yes">K</italic>i = 5.6 nM) and selectivity (S2R/S1R = 331), comparable to compound <bold>3</bold>. Notably, compound <bold>7,</bold> with a withdrawing nitro substituent, showed a lower S1R affinity (<italic toggle="yes">K</italic>i = 110 nM) together with a lower selectivity ratio (S2R/S1R = 59). Chloro and cyano compounds (<bold>2</bold>, <bold>3,</bold> and <bold>6</bold>) demonstrated excellent selectivity (S2R/S1R = 241&#8211;331), with strong S1R affinities (<italic toggle="yes">K</italic>i = 0.6&#8211;5.6 nM).</p><p>To assess potential cytotoxicity in CNS-relevant cells, human neuroblastoma (SH-SY5Y) cells were exposed to compounds <bold>2</bold>&#8211;<bold>7</bold> at concentrations up to 100 &#956;M. Cell viability was measured using the MTT assay. All compounds displayed minimal cytotoxicity, with IC<sub>50</sub> values exceeding 100 &#956;M and selectivity indices (IC<sub>50</sub>(SH-SY5Y)/<italic toggle="yes">K</italic>i(S1R)) ranging from 909 to 166,666 (<xref rid="molecules-30-03584-t001" ref-type="table">Table 1</xref>). In particular, compound <bold>2</bold>, combining high S1R affinity (<italic toggle="yes">K</italic>i = 0.6 nM) and selectivity (317), achieved the highest selectivity index of 166,666.</p></sec><sec id="sec2dot3-molecules-30-03584"><title>2.3. Docking Study of Compounds</title><p>To investigate the potential binding modes of these benzamide derivatives, compounds <bold>1</bold> and <bold>2</bold> were docked into the binding site of S1R [<xref rid="B18-molecules-30-03584" ref-type="bibr">18</xref>]. As illustrated in <xref rid="molecules-30-03584-f002" ref-type="fig">Figure 2</xref>, the retroamide modification in compound <bold>2</bold> resulted in a slight shift of the compound inside the binding pocket. This conformational shift enhanced the ionic interaction with Asp126 while preserving the key salt bridge with Glu172. Additionally, the new orientation enabled the formation of an extra hydrogen bond with the phenolic group of Tyr103, potentially contributing to the improved affinity observed for compound <bold>2</bold>. In contrast, the docking study did not provide a rationale for the pronounced loss of affinity observed with the brominated derivative <bold>4</bold>.</p></sec><sec id="sec2dot4-molecules-30-03584"><title>2.4. Off-Target Analysis over a Panel of 58 Recombinant Human Receptors</title><p>Among the synthesized compounds, four derivatives were selected based on their affinity and selectivity profiles. Compound <bold>5</bold>, exhibiting the lowest S2R/S1R selectivity [<xref rid="B17-molecules-30-03584" ref-type="bibr">17</xref>], and compound <bold>4</bold>, characterized by poor S1R affinity (<italic toggle="yes">K</italic>i &gt; 200 nM), were excluded from further evaluation. The remaining compounds (<bold>2</bold>, <bold>3</bold>, <bold>6</bold>, and <bold>7</bold>) were assessed for their agonist and antagonist activities across a panel of 58 receptors relevant to CNS disorders, including serotonin, adenosine, adrenergic, cannabinoid, dopamine, histamine, and muscarinic receptors. These assays were conducted at a concentration of 10 &#181;M, in duplicate, utilizing aequorin [<xref rid="B19-molecules-30-03584" ref-type="bibr">19</xref>], cAMP HTRF&#8482; [<xref rid="B20-molecules-30-03584" ref-type="bibr">20</xref>], and GTP&#947;S binding assays [<xref rid="B21-molecules-30-03584" ref-type="bibr">21</xref>], as detailed in <xref rid="molecules-30-03584-t002" ref-type="table">Table 2</xref>. None of the compounds exhibited significant agonist activity at 10 &#181;M, except for compound <bold>3</bold>, which showed moderate agonist activity at the 5-HT<sub>7</sub> serotonin receptor. In contrast, all tested compounds demonstrated antagonist activity at 10 &#181;M against adrenergic &#945;<sub>1</sub> and histamine H<sub>1</sub> receptors. Notably, the reference compound <bold>1</bold> showed no activity at the H<sub>1</sub> receptor. Compounds <bold>2</bold> and <bold>3</bold>, bearing chloro substituents at the <italic toggle="yes">meta</italic> and <italic toggle="yes">para</italic> positions of the benzyl ring, respectively, exhibited antagonist activity against eight and ten receptors, respectively. Conversely, compounds <bold>6</bold> and <bold>7</bold>, substituted with electron-withdrawing cyano and nitro groups, respectively, displayed antagonist activity at a limited number of receptors. Specifically, compound <bold>6</bold> antagonized four receptors (5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, &#945;<sub>1a</sub>, H<sub>1</sub>), while compound <bold>7</bold> was active against five receptors (5-HT<sub>2A</sub>, 5-HT<sub>3</sub>, &#945;<sub>1a</sub>, H<sub>1</sub>, M<sub>1</sub>). Both compounds <bold>6</bold> and <bold>7</bold> demonstrated profiles similar to the lead compound <bold>1</bold>, with antagonist activity targeting three adrenergic and muscarinic receptors (&#945;<sub>1a</sub>, &#945;<sub>1b</sub>, and M<sub>1</sub>).</p></sec><sec id="sec2dot5-molecules-30-03584"><title>2.5. Target Engagement and Agonist Profile of Selected Compounds</title><p>The interaction between S1R and BiP provides a reliable assay to identify S1R ligands by monitoring the dynamics of the S1R-BiP complex [<xref rid="B22-molecules-30-03584" ref-type="bibr">22</xref>,<xref rid="B23-molecules-30-03584" ref-type="bibr">23</xref>,<xref rid="B24-molecules-30-03584" ref-type="bibr">24</xref>]. In this assay, the known S1R agonist PRE-084 and antagonist NE-100 were used as controls (<xref rid="molecules-30-03584-f003" ref-type="fig">Figure 3</xref>). As shown in <xref rid="molecules-30-03584-f003" ref-type="fig">Figure 3</xref>, PRE-084 induced a rapid and transient dissociation of the S1R-BiP heterodimer (reducing complex levels to less than 50% of the control), whereas NE-100 prevented this dissociation, maintaining complex levels at 90&#8211;100% of the control, both in the presence and absence of PRE-084. In the present study, the most potent and selective compounds (<bold>2</bold>, <bold>3</bold>, and <bold>6</bold>) were evaluated using this assay. Compounds <bold>2</bold> and <bold>3</bold>, at concentrations of 1 and 10 &#181;M, induced a significant, dose-dependent dissociation of the S1R-BiP complex. In contrast, compound <bold>6</bold> produced only a slight and less significant reduction. The dissociation induced by compounds <bold>2</bold> and <bold>3</bold> was completely inhibited by NE-100 (10 &#181;M), confirming their agonist activity. Moreover, co-treatment with PRE-084 and the test compounds resulted in dissociation levels comparable to PRE-084 alone, indicating that these compounds do not antagonize PRE-084&#8217;s effect, thus validating the absence of the antagonist PRE-084.</p></sec><sec id="sec2dot6-molecules-30-03584"><title>2.6. ADME Studies of Selected Compounds</title><p>Based on activity, selectivity, and agonist profiles, compounds <bold>2</bold> and <bold>6</bold> were selected for advanced stages of drug development. The most promising candidate (compound <bold>2</bold>) bears a chloro substituent, while compound <bold>6</bold> is a cyano-substituted derivative.</p><p>Preliminary ADME evaluation focused on bioavailability properties at 10 &#181;M (<xref rid="molecules-30-03584-t003" ref-type="table">Table 3</xref>). Both compounds exhibited high solubility in PBS at pH 7.4 [<xref rid="B25-molecules-30-03584" ref-type="bibr">25</xref>]. Solubility and stability remained unchanged in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF), which mimic gastrointestinal digestion. Intestinal permeability was assessed using a two-chamber system with apical (A, pH 6.5) and basolateral (B, pH 7.4) compartments, representing the luminal and blood/mesenteric lymph sides of the gastrointestinal tract, respectively [<xref rid="B26-molecules-30-03584" ref-type="bibr">26</xref>]. Both compounds demonstrated good A-to-B permeability, with compound <bold>6</bold> showing higher permeability than compound <bold>2</bold>. The efflux ratios for both compounds ranged between 1 and 2, indicating improved permeability relative to the reference compound <bold>1</bold>. Both compounds displayed plasma stability exceeding 24 h. Plasma protein binding was high for compound <bold>2</bold> (98%), comparable to that of compound <bold>1</bold>, while compound <bold>6</bold> exhibited moderate binding (63%) [<xref rid="B27-molecules-30-03584" ref-type="bibr">27</xref>].</p><p>Microsomal stability was evaluated using human liver microsomes at 10 &#181;M (<xref rid="molecules-30-03584-t003" ref-type="table">Table 3</xref>). Compound <bold>6</bold> exhibited a half-life exceeding 1 h and favorable clearance (&lt;115 &#181;L/min/mg protein). In contrast, compound <bold>2</bold> had a shorter half-life (5 min) and higher clearance (135.3 &#181;L/min/mg protein). Since cytochrome P450 (CYP) enzymes&#8212;especially families 1 to 3&#8212;play major roles in drug metabolism [<xref rid="B28-molecules-30-03584" ref-type="bibr">28</xref>], CYP inhibition was tested against the human isoforms CYP1A, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A, as recommended by FDA and EMA guidelines. Both compounds exhibited no or weak inhibition, except for moderate inhibition of CYP2D6. Membrane transport proteins, including the ATP-binding cassette (ABC) and solute carrier (SLC) families, affect drug pharmacokinetics and potential drug&#8211;drug interactions [<xref rid="B29-molecules-30-03584" ref-type="bibr">29</xref>,<xref rid="B30-molecules-30-03584" ref-type="bibr">30</xref>,<xref rid="B31-molecules-30-03584" ref-type="bibr">31</xref>,<xref rid="B32-molecules-30-03584" ref-type="bibr">32</xref>,<xref rid="B33-molecules-30-03584" ref-type="bibr">33</xref>,<xref rid="B34-molecules-30-03584" ref-type="bibr">34</xref>,<xref rid="B35-molecules-30-03584" ref-type="bibr">35</xref>,<xref rid="B36-molecules-30-03584" ref-type="bibr">36</xref>,<xref rid="B37-molecules-30-03584" ref-type="bibr">37</xref>,<xref rid="B38-molecules-30-03584" ref-type="bibr">38</xref>]. The inhibitory effects of compounds <bold>2</bold> and <bold>6</bold> were assessed against five ABC transporters (P-gp, BCRP, MRP1, MRP2, and MRP3) and seven SLC transporters (OAT1, OAT3, OATP1B1, OCT1, OCT2, ASBT, and NTCP). Both compounds demonstrated low inhibitory activity (&lt;50% inhibition), comparable to that of compound <bold>1</bold>, indicating negligible transporter inhibition.</p><p>Cardiac toxicity is a leading cause of drug development failure. Early safety profiling includes evaluation of the potassium voltage-gated channel subfamily H member 2 (KCNH2 or hERG) channel, the only in vitro assay mandated by regulatory agencies to predict proarrhythmic risk [<xref rid="B29-molecules-30-03584" ref-type="bibr">29</xref>]. Compounds <bold>2</bold> and <bold>6</bold> inhibited hERG currents with IC<sub>50</sub> values in the micromolar range. Importantly, an IC<sub>50</sub> (hERG)/<italic toggle="yes">Ki</italic> (&#963;<sub>1</sub>) ratio exceeding 100 is advised for cardiac safety; all compounds met this criterion. Compound <bold>2</bold> was particularly notable, with an IC<sub>50</sub> (hERG)/<italic toggle="yes">Ki</italic> (&#963;<sub>1</sub>) ratio above 11,000, suggesting a high potential for cardiac safety.</p></sec></sec><sec id="sec3-molecules-30-03584"><title>3. Materials and Methods</title><sec id="sec3dot1-molecules-30-03584"><title>3.1. Chemistry</title><p>All chemicals and solvents were obtained from commercial suppliers and, unless stated otherwise, were used without further purification. Reaction progress was monitored by thin-layer chromatography (TLC) on Macherey-Nagel Alugram<sup>&#174;</sup> Sil 60/UV254 plates (0.2 mm; Macherey-Nagel GmbH &amp; Co. KG, D&#252;ren, Germany). Products were purified by column chromatography on Macherey-Nagel silica gel (230&#8211;400 mesh).</p><p>The <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker DRX 300 spectrometer (300 and 75 MHz, respectively; Division Biospin, Wissembourg, France). Chemical shifts are reported in ppm relative to tetramethylsilane (TMS) and described as &#948; (ppm), multiplicity (s, d, t, q, p, dd, br, m), coupling constant (<italic toggle="yes">J</italic>, Hz), integration, and assignment.</p><p>Mass spectra for compounds <bold>9a</bold>&#8211;<bold>f</bold> and <bold>2</bold>&#8211;<bold>7</bold> were acquired with unit mass accuracy using an LCMS system (Waters Alliance Micromass ZQ 2000; Waters Corporation, Milford, MA, USA) equipped with PDA detection, an electrospray ionization (ESI) source, and a Waters XBridge C18 column (5 &#956;m, 50 &#215; 4.6 mm). The mobile phase consisted of a 4 min gradient from 98% H<sub>2</sub>O/formate buffer (5 mM, pH 3.8) to 100% CH<sub>3</sub>CN/formate buffer (5 mM, pH 3.8) at a flow rate of 2 mL/min, followed by 1 min re-equilibration.</p><p><bold>General Procedure for the Preparation of 3-Chloro-<italic toggle="yes">N</italic>-(4-substitutedbenzyl)propanamide (9a&#8211;f):</bold> To a solution of 4-substituted benzylamine <bold>8a</bold>&#8211;<bold>f</bold> (7.0 mmol) in 15 mL of DCM at 0 &#176;C, a solution of 3-chloropropionyl chloride (7.0 mmol, 668 &#181;L) was slowly added in 5 mL of DCM. The resulting mixture was stirred at room temperature for 12 h. Then, the reaction was quenched with 20 mL of water, and the product was extracted with 3 &#215; 25 mL of DCM. The combined organic fractions were dried over magnesium sulfate. The crude product was purified by column chromatography.</p><p><bold><italic toggle="yes">N</italic>-(3-Chlorobenzyl)-3-chloropropanamide (9a):</bold> Yield: 73%. <italic toggle="yes">R</italic>f (DCM: MeOH (saturated with gaz NH<sub>3</sub>) 9.5/0.5) = 0.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 7.40&#8211;7.10 (m, 4H, H<sub>aro</sub>); 6.10 (br s, 1H, NH); 4.43 (d, <italic toggle="yes">J</italic> = 6.2 Hz, 2H, CH<sub>2</sub>); 3.80 (t, <italic toggle="yes">J</italic> = 6.4 Hz, 2H, CH<sub>2</sub>); 2.65 (t, <italic toggle="yes">J</italic> = 6.3 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 169.6 (CO); 139.9 (C<sub>aro</sub>); 134.5 (C<sub>aro</sub>); 130.0 (C<sub>aro</sub>); 137.7 (C<sub>aro</sub>); 125.8 (C<sub>aro</sub>); 43.1 (CH<sub>2</sub>); 40.1 (CH<sub>2</sub>); 39.5 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>10</sub>H<sub>12</sub>Cl<sub>2</sub>NO [M + H]<sup>+</sup>: 232.0, 234.0, 236.0; found: 231.9, 233.9, 235.9.</p><p><bold><italic toggle="yes">N</italic>-(4-Chlorobenzyl)-3-chloropropanamide (9b):</bold> Yield: 60%. <italic toggle="yes">R</italic>f (ethyl acetate: cyclohexane, 5:5) = 0.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 7.35&#8211;7.30 (m, 2H, H<sub>aro</sub>); 7.25&#8211;7.20 (m, 2H, H<sub>aro</sub>); 5.94 (br s, 1H, NH); 4.45 (d, <italic toggle="yes">J</italic> = 6.2 Hz, 2H, CH<sub>2</sub>); 3.84 (t, <italic toggle="yes">J</italic> = 6.4 Hz, 2H, CH<sub>2</sub>); 2.67 (t, <italic toggle="yes">J</italic> = 6.3 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 169.4 (CO); 136.4 (C<sub>aro</sub>); 133.4 (C<sub>aro</sub>); 129.1 (C<sub>aro</sub>); 128.9 (C<sub>aro</sub>); 43.1 (CH<sub>2</sub>); 40.1 (CH<sub>2</sub>); 39.6 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>10</sub>H<sub>12</sub>Cl<sub>2</sub>NO [M + H]<sup>+</sup>: 232.0, 234.0, 236.0; found: 232.1, 234.1, 236.1.</p><p><bold><italic toggle="yes">N</italic>-(4-Bromobenzyl)-3-chloropropanamide (9c):</bold> Yield: 67%. <italic toggle="yes">R</italic>f (DCM: MeOH (saturated with gaz NH<sub>3</sub>) 9.5/0.5) = 0.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 7.50&#8211;7.40 (m, 2H, H<sub>aro</sub>); 7.30&#8211;7.15 (m, 2H, H<sub>aro</sub>); 6.10 (br s, 1H, NH); 4.45 (d, <italic toggle="yes">J</italic> = 5.9 Hz, 2H, CH<sub>2</sub>); 3.83 (t, <italic toggle="yes">J</italic> = 6.4 Hz, 2H, CH<sub>2</sub>); 2.68 (t, <italic toggle="yes">J</italic> = 6.4 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 169.5 (CO); 140.2 (C<sub>aro</sub>); 130.7 (C<sub>aro</sub>); 130.6 (C<sub>aro</sub>); 130.3 (C<sub>aro</sub>); 126.3 (C<sub>aro</sub>); 122.7 (C<sub>aro</sub>); 43.1 (CH<sub>2</sub>); 40.1 (CH<sub>2</sub>); 39.5 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>10</sub>H<sub>12</sub>BrClNO [M + H]<sup>+</sup>: 275.9, 277.9, 279.9; found: 275.8, 277.8, 279.8.</p><p><bold>3-Chloro<italic toggle="yes">-N</italic>-(2,4-dichlorobenzyl)propanamide (9d):</bold> Yield: 79%. <italic toggle="yes">R</italic>f (DCM: MeOH (saturated with gaz NH<sub>3</sub>) 9.5/0.5) = 0.6. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 7.40 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H, H<sub>aro</sub>); 7.36 (d, <italic toggle="yes">J</italic> = 8.2 Hz, 1H, H<sub>aro</sub>); 7.23 (dd, <italic toggle="yes">J</italic> = 8.2 Hz, <italic toggle="yes">J</italic> = 2.1 Hz, 1H, H<sub>aro</sub>); 6.05 (br s, 1H, NH); 4.53 (d, <italic toggle="yes">J</italic> = 6.1 Hz, 2H, CH<sub>2</sub>); 3.83 (t, <italic toggle="yes">J</italic> = 6.4 Hz, 2H, CH<sub>2</sub>); 2.68 (t, <italic toggle="yes">J</italic> = 6.4 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 169.6 (CO); 134.1 (C<sub>aro</sub>); 134.0 (C<sub>aro</sub>); 133.9 (C<sub>aro</sub>); 130.8 (C<sub>aro</sub>); 129.3 (C<sub>aro</sub>); 127.4 (C<sub>aro</sub>); 41.0 (CH<sub>2</sub>); 40.0 (CH<sub>2</sub>); 39.4 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>10</sub>H<sub>10</sub>Cl<sub>3</sub>NO [M &#8722; H]<sup>&#8722;</sup>: 264.0, 266.0, 268.0, 270.0; found: 263.8, 265.8, 267.9, 269.9.</p><p><bold>3-Chloro<italic toggle="yes">-N</italic>-(4-cyanobenzyl)propanamide (9e):</bold> Yield: 65%. <italic toggle="yes">R</italic>f (DCM: MeOH (saturated with gaz NH<sub>3</sub>) 9.5/0.5) = 0.6. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 7.62 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H, H<sub>aro</sub>); 7.48 (d, <italic toggle="yes">J</italic> = 8.1 Hz, 2H, H<sub>aro</sub>); 6.05 (br s, 1H, NH); 4.55 (d, <italic toggle="yes">J</italic> = 6.1 Hz, 2H, CH<sub>2</sub>); 3.85 (t, <italic toggle="yes">J</italic> = 6.3 Hz, 2H, CH<sub>2</sub>); 2.70 (t, <italic toggle="yes">J</italic> = 6.3 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 169.9 (CO); 143.7 (C<sub>aro</sub>); 132.4 (C<sub>aro</sub>); 128.1 (C<sub>aro</sub>); 118.7 (C<sub>aro</sub>); 111.1 (C<sub>aro</sub>); 43.1 (CH<sub>2</sub>); 40.1 (CH<sub>2</sub>); 39.4 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>11</sub>H<sub>10</sub>ClN<sub>2</sub>O [M &#8722; H]<sup>&#8722;</sup>: 221.0, 223.0; found: 220.9, 222.9.</p><p><bold>3-Chloro<italic toggle="yes">-N</italic>-(4-nitrobenzyl)propanamide (9f):</bold> Yield: 69%. <italic toggle="yes">R</italic>f (DCM: MeOH (saturated with gaz NH<sub>3</sub>) 9.5/0.5) = 0.6. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 8.20 (d, <italic toggle="yes">J</italic> = 8.8 Hz, 2H, H<sub>aro</sub>); 7.48 (d, <italic toggle="yes">J</italic> = 8.9 Hz, 2H, H<sub>aro</sub>); 6.05 (br s, 1H, NH); 4.60 (d, <italic toggle="yes">J</italic> = 6.2 Hz, 2H, CH<sub>2</sub>); 3.85 (t, <italic toggle="yes">J</italic> = 6.3 Hz, 2H, CH<sub>2</sub>); 2.70 (t, <italic toggle="yes">J</italic> = 6.2 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 169.7 (CO); 145.5 (C<sub>aro</sub>); 128.2 (C<sub>aro</sub>); 124.0 (C<sub>aro</sub>); 123.9 (C<sub>aro</sub>); 43.0 (CH<sub>2</sub>); 40.1 (CH<sub>2</sub>); 39.5 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>10</sub>H<sub>10</sub>ClN<sub>2</sub>O<sub>3</sub> [M &#8722; H]<sup>&#8722;</sup>: 241.0, 243.0; found: 240.8, 242.8.</p><p><bold>General Procedure for the Preparation of 3-(Benzylmethylamino)-<italic toggle="yes">N</italic>-(substitutedbenzyl)propanamide (2-7)</bold>: A solution of compounds <bold>9a</bold>&#8211;<bold>f</bold> (1 eq) in <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-benzylmethylamine (6 eq) was stirred at room temperature for 18 h. A 5 mL amount of cyclohexane was added, and the white solid was filtered. The filtrate was concentrated and purified by thick-layer chromatography or column chromatography.</p><p><bold>3-(Benzylmethylamino)-<italic toggle="yes">N</italic>-(3-chlorobenzyl)propanamide (2):</bold> Compound <bold>2</bold> was synthesized by using <italic toggle="yes">N</italic>-(3-chlorobenzyl)-3-chloropropanamide <bold>9a</bold> (0.43 mmol, 100 mg) and <italic toggle="yes">N</italic>-benzylmethylamine (4.3 mmol, 555 &#181;L). Purification by thick-layer chromatography (DCM: MeOH(NH<sub>3</sub>), 9.5:0.5, <italic toggle="yes">R</italic>f = 0.3). Yield: 68%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 8.80 (br s, 1H, NH); 7.30&#8211;7.00 (m, 9H, H<sub>aro</sub>); 4.40 (d, <italic toggle="yes">J</italic> = 5.6 Hz, 2H, CH<sub>2</sub>); 3.50 (s, 2H, CH<sub>2</sub>); 2.70 (t, <italic toggle="yes">J</italic> = 6.0 Hz, 2H, CH<sub>2</sub>); 2.48 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 2H, CH<sub>2</sub>); 2.20 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 172.5 (CO); 140.8 (C<sub>aro</sub>); 137.5 (C<sub>aro</sub>); 134.4 (C<sub>aro</sub>); 129.9 (C<sub>aro</sub>); 129.0 (C<sub>aro</sub>); 128.5 (C<sub>aro</sub>); 127.8 (C<sub>aro</sub>); 127.5 (C<sub>aro</sub>); 127.4 (C<sub>aro</sub>); 125.9 (C<sub>aro</sub>); 62.2 (CH<sub>2</sub>); 53.1 (CH<sub>2</sub>); 42.5 (CH<sub>3</sub>); 40.1 (CH<sub>2</sub>); 32.6 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>18</sub>H<sub>22</sub>ClN<sub>2</sub>O [M + H]<sup>+</sup>: 317.1, 319.1; found: 317.1, 319.1.</p><p><bold>3-(Benzylmethylamino)-<italic toggle="yes">N</italic>-(4-chlorobenzyl)propanamide (3):</bold> Compound <bold>3</bold> was synthesized by using <italic toggle="yes">N</italic>-(4-chlorobenzyl)-3-chloropropanamide <bold>9b</bold> (0.21 mmol, 50 mg) and <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-benzylmethylamine (1.29 mmol, 166 &#181;L). Purification by thick-layer chromatography with cyclohexane/ethyl acetate/MeOH (saturated with gas NH<sub>3</sub>), 4.5:4.5:1, <italic toggle="yes">R</italic>f = 0.4. Yield: 67%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 8.65 (br s, 1H, NH); 7.34&#8211;7.19 (m, 7H, H<sub>2</sub>, H<sub>6</sub>, H<sub>aro</sub>); 7.09 (d, <italic toggle="yes">J</italic> = 9.3 Hz, 2H, H<sub>3</sub>, H<sub>5</sub>); 4.38 (d, <italic toggle="yes">J</italic> = 6.1 Hz, 2H, CH<sub>2</sub>); 3.57 (s, 2H, CH<sub>2</sub>); 2.79 (t, <italic toggle="yes">J</italic> = 6.2 Hz, 2H, CH<sub>2</sub>); 2.56 (t, <italic toggle="yes">J</italic> = 6.0 Hz, 2H, CH<sub>2</sub>); 2.25 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 171.9 (CO); 137.2 (C<sub>aro</sub>); 133.1 (C<sub>aro</sub>); 129.3 (2 C<sub>aro</sub>); 129.2 (3 C<sub>aro</sub>); 128.8 (2 C<sub>aro</sub>); 128.6 (2 C<sub>aro</sub>); 127.9 (C<sub>aro</sub>); 62.0 (CH<sub>2</sub>); 53.0 (CH<sub>2</sub>); 42.6 (CH<sub>2</sub>); 40.7 (CH<sub>3</sub>); 32.4 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>18</sub>H<sub>22</sub>ClN<sub>2</sub>O [M + H]<sup>+</sup>: 317.1, 319.1; found: 316.9, 319.0.</p><p><bold>3-(Benzylmethylamino)-<italic toggle="yes">N</italic>-(3-bromobenzyl)propanamide (4):</bold> Compound <bold>4</bold> was synthesized by using <italic toggle="yes">N</italic>-(4-bromobenzyl)-3-chloropropanamide <bold>9c</bold> (0.21 mmol, mg) and <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-benzylmethylamine (1.29 mmol, 166 &#181;L). Purification by thick-layer chromatography (DCM/MeOH (saturated with gas NH<sub>3</sub>) 9.5/0.5, <italic toggle="yes">R</italic>f = 0.3). Yield: 74%. %. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 8.84 (br s, 1H, NH); 7.43&#8211;7.40 (m, 2H, H<sub>aro</sub>); 7.27&#8211;7.17 (m, 5H, H<sub>aro</sub>); 7.06&#8211;7.02 (m, 2H, H<sub>aro</sub>); 4.39 (d, <italic toggle="yes">J</italic> = 5.7 Hz, 2H, CH<sub>2</sub>); 3.48 (s, 2H, CH<sub>2</sub>); 2.68 (t, <italic toggle="yes">J</italic> = 5.2 Hz, 2H, CH<sub>2</sub>); 2.48 (t, <italic toggle="yes">J</italic> = 5.3 Hz, 2H, CH<sub>2</sub>); 2.20 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 172.4 (CO); 141.2 (C<sub>aro</sub>); 137.6 (C<sub>aro</sub>); 130.7 (C<sub>aro</sub>); 130.4 (C<sub>aro</sub>); 130.2 (C<sub>aro</sub>); 130.0 (C<sub>aro</sub>); 128.5 (C<sub>aro</sub>); 127.5 (C<sub>aro</sub>); 126.4 (C<sub>aro</sub>); 122.7 (C<sub>aro</sub>); 62.3 (CH<sub>2</sub>); 53.1 (CH<sub>2</sub>); 42.5 (CH<sub>3</sub>); 41.0 (CH<sub>2</sub>); 32.6 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>18</sub>H<sub>22</sub>BrN<sub>2</sub>O [M + H]<sup>+</sup>: 361.1, 363.1; found: 361.0, 363.0.</p><p><bold>3-(Benzylmethylamino)-<italic toggle="yes">N</italic>-(2,4-Dichlorobenzyl)propanamide (5):</bold> Compound <bold>5</bold> was synthesized by using 3-chloro-<italic toggle="yes">N</italic>-(2,4-dichlorobenzyl)propanamide <bold>9d</bold> (0.37 mmol, 100 mg) and <italic toggle="yes">N</italic>-benzylmethylamine (3.7 mmol, 483 &#181;L). Purification by thick-layer chromatography (DCM: MeOH(NH<sub>3</sub>), 9.7:0.3, <italic toggle="yes">R</italic>f = 0.3). Yield: 80%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 8.90 (br s, 1H, NH); 7.38 (d, <italic toggle="yes">J</italic> = 1.9 Hz, 1H, H<sub>aro</sub>); 7.28 (d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H, H<sub>aro</sub>); 7.27&#8211;7.15 (m, 4H, H<sub>aro</sub>); 7.10 (m, 2H, H<sub>aro</sub>); 4.45 (d, <italic toggle="yes">J</italic> = 5.8 Hz, 2H, CH<sub>2</sub>); 3.50 (s, 2H, CH<sub>2</sub>); 2.70 (t, <italic toggle="yes">J</italic> = 6.1 Hz, 2H, CH<sub>2</sub>); 2.45 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 2H, CH<sub>2</sub>); 2.18 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 172.5 (CO); 137.5 (C<sub>aro</sub>); 134.8 (C<sub>aro</sub>); 134.3 (C<sub>aro</sub>); 133.7(C<sub>aro</sub>); 131.1 (C<sub>aro</sub>); 129.2 (C<sub>aro</sub>); 129.0 (C<sub>aro</sub>); 128.4 (C<sub>aro</sub>); 127.5 (C<sub>aro</sub>); 127.3 (C<sub>aro</sub>); 62.2 (CH<sub>2</sub>); 53.1 (CH<sub>2</sub>); 41.0 (CH<sub>3</sub>); 40.5 (CH<sub>2</sub>); 32.6 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>18</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>2</sub>O [M + H]<sup>+</sup>: 351.1, 353.1, 355.1; found: 351.0, 352.9, 355.0 [M + H]<sup>+</sup>.</p><p><bold>3-(Benzylmethylamino)-<italic toggle="yes">N</italic>-(4-cyanobenzyl)propanamide (6):</bold> Compound <bold>6</bold> was synthesized by using 3-chloro<italic toggle="yes">-N</italic>-(4-cyanobenzyl)propanamide <bold>9e</bold> (0.44 mmol, 100 mg) and <italic toggle="yes">N</italic>-benzylmethylamine (4.4 mmol, 579 &#181;L). Purification by thick-layer chromatography (DCM: MeOH(NH<sub>3</sub>), 9.5:0.5, <italic toggle="yes">R</italic>f = 0.3). Yield: 80%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 8.90 (br s, 1H, NH); 7.58 (d, <italic toggle="yes">J</italic> = 6.3 Hz, 2H, H<sub>aro</sub>); 7.32 (d, <italic toggle="yes">J</italic> = 8.1 Hz, 2H, H<sub>aro</sub>); 7.21 (m, 3H, H<sub>aro</sub>); 7.07 (m, 2H, H<sub>aro</sub>); 4.43 (d, <italic toggle="yes">J</italic> = 5.9 Hz, 2H, CH<sub>2</sub>); 3.48 (s, 2H, CH<sub>2</sub>); 2.68 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 2H, CH<sub>2</sub>); 2.47 (t, <italic toggle="yes">J</italic> = 5.5 Hz, 2H, CH<sub>2</sub>); 2.21 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 172.7 (CO); 144.4 (C<sub>aro</sub>); 137.5 (C<sub>aro</sub>); 132.4 (C<sub>aro</sub>); 129.0 (C<sub>aro</sub>); 128.5 (C<sub>aro</sub>); 128.1 (C<sub>aro</sub>); 127.5 (C<sub>aro</sub>); 118.8 (CN); 110.9 (C<sub>aro</sub>); 62.2 (CH<sub>2</sub>); 52.9 (CH<sub>2</sub>); 42.5 (CH<sub>3</sub>); 41.1 (CH<sub>2</sub>); 32.6 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>19</sub>H<sub>22</sub>N<sub>3</sub>O [M + H]<sup>+</sup>: 308.2; found: 308.2 [M + H]<sup>+</sup>.</p><p><bold>3-(Benzylmethylamino)-<italic toggle="yes">N</italic>-(4-Nitrobenzyl)propanamide (7):</bold> Compound <bold>7</bold> was synthesized by using 3-chloro<italic toggle="yes">-N</italic>-(4-nitrobenzyl)propanamide <bold>9f</bold> (0.41 mmol, 100 mg) and <italic toggle="yes">N</italic>-benzylmethylamine (4.1 mmol, 531 &#181;L). Purification by thick-layer chromatography (DCM: MeOH(NH<sub>3</sub>), 9.5:0.5 (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>), <italic toggle="yes">R</italic>f = 0.3). Yield: 37%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), &#948;: 9.00 (br s, 1H, NH); 8.15 (d, <italic toggle="yes">J</italic> = 8.7 Hz, 2H, H<sub>aro</sub>); 7.40 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 2H, H<sub>aro</sub>); 7.20 (m, 3H, H<sub>aro</sub>); 7.10 (m, 2H, H<sub>aro</sub>); 4.50 (d, <italic toggle="yes">J</italic> = 6.0 Hz, 2H, CH<sub>2</sub>); 3.50 (s, 2H, CH<sub>2</sub>); 2.70 (t, <italic toggle="yes">J</italic> = 6.2 Hz, 2H, CH<sub>2</sub>); 2.50 (t, <italic toggle="yes">J</italic> = 6.2 Hz, 2H, CH<sub>2</sub>); 2.25 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#948;: 172.6 (CO); 146.5 (C<sub>aro</sub>); 146.2 (C<sub>aro</sub>); 137.3 (C<sub>aro</sub>); 129.1 (C<sub>aro</sub>); 128.5 (C<sub>aro</sub>); 128.1 (C<sub>aro</sub>); 127.6 (C<sub>aro</sub>); 123.8 (C<sub>aro</sub>); 62.2 (CH<sub>2</sub>); 52.8 (CH<sub>2</sub>); 42.3 (CH<sub>3</sub>); 41.1 (CH<sub>2</sub>); 32.5 (CH<sub>2</sub>); 29.7 (CH<sub>2</sub>). LCMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc for C<sub>18</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 328.1; found: 327.9 [M + H]<sup>+</sup>.</p></sec><sec id="sec3dot2-molecules-30-03584"><title>3.2. Biological Activity</title><sec id="sec3dot2dot1-molecules-30-03584"><title>3.2.1. Assay for Binding to Sigma Receptors</title><p>Binding assays were performed by Eurofins Cerep (Poitiers, France) according to the protocol of Ganapathy [<xref rid="B17-molecules-30-03584" ref-type="bibr">17</xref>]. For the S1R assay, Jurkat cell membranes (10&#8211;20 &#956;g protein/tube) were incubated at 37 &#176;C for 2 h in 5 mM Tris-HCl buffer (pH 7.4) with <sup>3</sup>H-pentazocine (15 nM) and varying concentrations of the test compounds. Under these experimental conditions, the Kd of this radioligand was measured as 16 nM. For the S2R assay, Jurkat cell membranes (10&#8211;20 &#956;g protein/tube) were incubated at room temperature for 1 h in the same buffer with [<sup>3</sup>H]-DTG (25 nM) in the presence of (+)-pentazocine (1 &#956;M) to saturate S1R, along with a range of test compound concentrations. Bound radioactivity was quantified by liquid scintillation counting. Nonspecific binding was determined under identical conditions in the presence of 10 &#956;M unlabeled haloperidol. The IC<sub>50</sub> values (concentration causing a half-maximal inhibition of control-specific binding) and Hill coefficients (nH) were determined by non-linear regression analysis of the competition curves generated with mean replicate values using Hill equation curve-fitting. This analysis was performed using software developed at Cerep (Hill software) and validated by comparison with data generated by the commercial software SigmaPlot <sup>&#174;</sup>4.0 for Windows<sup>&#174;</sup> (&#169;1997 by SPSS Inc.). Inhibition constants (<italic toggle="yes">K</italic>i) were calculated from IC<sub>50</sub> values using the method of Cheng and Prusoff [<xref rid="B39-molecules-30-03584" ref-type="bibr">39</xref>].</p></sec><sec id="sec3dot2dot2-molecules-30-03584"><title>3.2.2. Assay for Cytotoxicity</title><p>Cytotoxicity was assessed in human SH-SY5Y neuroblastoma cells cultured in Dulbecco&#8217;s Modified Eagle Medium (DMEM, Gibco, Thermo Fisher Scientific Inc., Waltham, MA, USA) supplemented with 2 mM L-glutamine, 100 &#956;g/mL streptomycin, 100 IU/mL penicillin, 1 mM non-essential amino acids (all from Invitrogen, Thermo Fisher Scientific Inc., Waltham, MA, USA), and 10% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) heat-inactivated fetal bovine serum (Sigma-Aldrich, Burlington, MA, USA). Cells were maintained at 37 &#176;C in a humidified 5% CO<sub>2</sub> atmosphere and serum-starved for 24 h to synchronize cultures before treatment with the test compounds at final concentrations of 100, 50, 10, 5, 1, 0.5, 0.1, or 0.05 &#956;M (all in &lt;0.1% DMSO). After 72 h, viability was determined using the MTT-based CellTiter 96<sup>&#174;</sup> AQueous One Solution Cell Proliferation Assay (MTS, Promega, Madison, WI, USA), following the manufacturer&#8217;s protocol. Absorbance was measured at 490 nm, and the results were expressed as a percentage relative to untreated control cells (set at 100%).</p></sec><sec id="sec3dot2dot3-molecules-30-03584"><title>3.2.3. Selectivity Profile (Agonist and Antagonist Activities) over a Panel of 58 Recombinant Human Receptors</title><p>Rapidly, the tests were performed by Euroscreen (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://euroscreenfast.com/">https://euroscreenfast.com/</uri>) with recombinant human G-coupled receptor-expressing cell lines using aequorin functional assays for serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, and 5-HT<sub>5A</sub>, adrenergic &#945;<sub>1a</sub> and &#945;<sub>1b</sub>, angiotensin AT<sub>1</sub>, cholesistokinin CCFK1, endothelin ETA, histamine H<sub>1</sub>, muscarinic M<sub>1</sub> and M<sub>3</sub>, neurokinin NK<sub>1</sub> and NK<sub>2</sub>, vasopressin V<sub>1a</sub>, and vasoactive intestinal peptide VPAC<sub>1</sub> receptor analysis [<xref rid="B20-molecules-30-03584" ref-type="bibr">20</xref>]. Then, cAMP HTRF<sup>TM</sup> assays were used to analyze serotonin 5-HT<sub>1A</sub>, 5-HT<sub>4E</sub>, 5-HT<sub>6</sub>, and 5-HT<sub>7</sub>, adenosine A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub>, adrenergic &#946;<sub>1</sub> and &#946;<sub>2</sub>, cannabinoid CB<sub>1</sub>, dopamine D<sub>1</sub>, histamine H<sub>2</sub>, and neuropeptide Y NPY receptors [<xref rid="B20-molecules-30-03584" ref-type="bibr">20</xref>]. GTP&#947;S<sup>35</sup> assays were used to analyze serotonin 5-HT<sub>1B</sub>, adrenergic &#945;<sub>2a</sub> and &#945;<sub>2b</sub>, dopamine D<sub>2</sub>, muscarinic M<sub>2</sub> and M<sub>4</sub>, opioid &#948;, &#954; and &#181;, and somatostatine SST4 receptors [<xref rid="B21-molecules-30-03584" ref-type="bibr">21</xref>].</p><p>Agonist and antagonist activities of the test compound are expressed as the percentage of the activity of the reference agonist at its EC<sub>100</sub> concentration or the percentage of inhibition of the reference agonist activity at its EC<sub>80</sub> concentration, respectively.</p><p>For the aequorin assays, different cell lines co-expressing the receptors were grown in specific culture media and incubated for 4 h with coelenterazine h. For agonist testing, cell suspensions were mixed with test or reference agonists in a 96-well plate. For antagonist testing, the reference agonist at its EC<sub>80</sub> (final concentration) was injected to the mix the containing cells and the tested compound. The resulting emission of light was recorded using the Hamamatsu Functional Drug Screening System 6000 [<xref rid="B19-molecules-30-03584" ref-type="bibr">19</xref>].</p><p>For the cAMP HTRF<sup>TM</sup> assays, different cell lines co-expressing the receptors were grown in specific culture media and resuspended in assay buffer. For agonist testing on Gs-coupled receptors, the tested compound was added at increasing concentrations. For antagonist testing, the tested compound and the reference agonist at its EC<sub>80</sub> (final concentration) were added. For agonist and antagonist testing on Gi-coupled receptors, forskolin was added to the reagents listed above. After incubation, cells were lysed and cAMP concentrations were estimated with the HTRF kit, according to the manufacturer&#8217;s specifications [<xref rid="B20-molecules-30-03584" ref-type="bibr">20</xref>].</p><p>For the GTP&#947;S scintillation proximity assay, optimized specific conditions were determined for each receptor. Membrane extracts were prepared from different cell lines co-expressing the receptors, mixed with GDP, and incubated on ice. For agonist testing, the tested compound or the reference agonist, GDP mix, and GTP&#947;[<sup>35</sup>S] were added. For antagonist testing, the tested compound or the reference antagonist, the reference agonist at historical EC80, GDP mix, and GTP&#947;[<sup>35</sup>S] were added. GTP concentrations were estimated with a PerkinElmer TopCount reader [<xref rid="B21-molecules-30-03584" ref-type="bibr">21</xref>].</p></sec><sec id="sec3dot2dot4-molecules-30-03584"><title>3.2.4. In Vitro Evaluation of S1R Functionality</title><p>The ability of the compounds to promote dissociation of the S1R&#8211;BiP complex was assessed by Amylgen (Montferrier-sur-Lez, France) as described in [<xref rid="B22-molecules-30-03584" ref-type="bibr">22</xref>,<xref rid="B23-molecules-30-03584" ref-type="bibr">23</xref>]. CHO cells were treated with the test compounds for 30 min at 37 &#176;C, followed by crosslinking with dithiobis(succinimidyl propionate) (DSP; Thermo Scientific, Waltham, MA, USA). Cells were lysed after 15 min on ice, and the lysates were centrifuged. Supernatants were incubated overnight at 4 &#176;C with an anti-S1R antibody (Abcam, Cambridge, UK), and then with Protein A-Sepharose (Invitrogen). After the first centrifugation, pellets were resuspended in radioimmunoprecipitation assay (RIPA) buffer, centrifuged again, and resuspended in 2&#215; sample buffer/bMCE buffer. Following a third centrifugation, the supernatants were analyzed for BiP immunoreactivity using an ELISA kit (SEC343Mu, USCNK Life Sciences, Wuhan, China).</p></sec><sec id="sec3dot2dot5-molecules-30-03584"><title>3.2.5. Physicochemical Properties</title><p>Standardized in vitro ADME experiments were performed by Eurofins Cerep (Poitiers, France). Solubility assays were performed in PBS at pH 7.4, but also in simulated gastric fluid (SGF) and intestinal fluid (SIF), through the classical shake-flask method described by Lipinski et al., using HPLC-UV/VIS technology [<xref rid="B25-molecules-30-03584" ref-type="bibr">25</xref>]. The results were expressed in &#181;M. The compound was classically evaluated at 10 &#181;M for all of the ADME analyses. Bidirectional permeability (apical A to basolateral B pH 6.5/7.4, and basolateral B to apical A pH 7.4/6.5) was assessed in the epithelial colorectal adenocarcinoma cell line (Caco-2 cell line) [<xref rid="B26-molecules-30-03584" ref-type="bibr">26</xref>]. The results were expressed as &#215;10<sup>&#8722;6</sup> cm/s (Papp) and as % recovery. The efflux ratio, i.e., Papp (B&#8594;A)/Papp(A&#8594;B), was calculated. Plasma protein binding was analyzed by HPLC-MS/MS after 4 h of incubation at 37 &#176;C, as described by Banker et al. [<xref rid="B27-molecules-30-03584" ref-type="bibr">27</xref>]. Concentration was evaluated by LC/MS-MS. CYP inhibition was performed in human liver microsomes as described in [<xref rid="B28-molecules-30-03584" ref-type="bibr">28</xref>]. Analysis of the respective metabolites was performed by HPLC-MS/MS. Transporter inhibition analysis was also performed in overexpressing cell lines. Respective metabolites for each specific transporter substrate were analyzed by fluorometry or scintillation counting, and % inhibition of control values were calculated [<xref rid="B29-molecules-30-03584" ref-type="bibr">29</xref>,<xref rid="B30-molecules-30-03584" ref-type="bibr">30</xref>,<xref rid="B31-molecules-30-03584" ref-type="bibr">31</xref>,<xref rid="B32-molecules-30-03584" ref-type="bibr">32</xref>,<xref rid="B33-molecules-30-03584" ref-type="bibr">33</xref>,<xref rid="B34-molecules-30-03584" ref-type="bibr">34</xref>,<xref rid="B35-molecules-30-03584" ref-type="bibr">35</xref>,<xref rid="B36-molecules-30-03584" ref-type="bibr">36</xref>,<xref rid="B37-molecules-30-03584" ref-type="bibr">37</xref>,<xref rid="B38-molecules-30-03584" ref-type="bibr">38</xref>]. P-glycoprotein transporter substrate assessment was performed by bidirectional permeability analysis (apical A to basolateral B pH 7.4/7.4, and basolateral B to apical A pH 7.4/7.4) in the Caco-2 cell line with and without verapamil, as described in [<xref rid="B26-molecules-30-03584" ref-type="bibr">26</xref>]. The results were expressed as &#215;10<sup>&#8722;6</sup> cm/s (Papp) and as % recovery. The efflux ratio was calculated as Papp(B&#8594;A)/Papp(A&#8594;B). CYP450 induction was assessed in human hepatocytes by measuring the mRNA levels of seven CYP isoforms via qPCR, as described in [<xref rid="B40-molecules-30-03584" ref-type="bibr">40</xref>]. The compound was tested at 1, 10, and 100 &#956;M, and fold-induction values were compared with predefined cut-off thresholds for each isoform and hepatocyte lot.</p><p>Plasma stability was evaluated by M2SV (Lille, France) in duplicate. Male CD-1 mouse plasma (lithium-heparinized; Sera Laboratories International Ltd. BioIVT, West Sussex, UK) was pre-incubated for 10 min at 37 &#176;C before addition of the test compound (final concentration 10 &#956;M, 0.1% DMSO). At 0, 60, 1440, and 2880 min, aliquots were transferred to chilled tubes containing acetonitrile and propranolol (1 &#956;M) as internal standard. After mixing and centrifugation (10 min, 10,000 rpm), the supernatants were analyzed, and their degradation half-lives (t<sub>1</sub>/<sub>2</sub>, min and h) were determined by non-linear regression using the Microsoft<sup>&#174;</sup> XLfit<sup>&#174;</sup> Excel add-in (IDBS Ltd., Woking, UK).</p><p>Cardiotoxicity analysis was performed by Eurofins Cerep (Poitiers, France) as described in [<xref rid="B41-molecules-30-03584" ref-type="bibr">41</xref>]. Rapidly, hERG CHO-K1 cells were used to perform automated whole-cell patch-clamp. Compounds were evaluated in duplicate from 0.1 to 10 &#181;M. The degree of inhibition (%) was determined by measuring the tail current amplitude, which was induced by a one-second test pulse to &#8722;40 mV after a two-second pulse to +20 mV, before and after drug incubation for 5 min at room temperature. After normalization, activities were expressed as the % inhibition of tail current. Concentration-(log) response curves were fitted to a logistic equation to generate estimates of the 50% inhibitory concentration (IC<sub>50</sub>). The concentration&#8211;response relationship of each compound was constructed from the percentage reductions in current amplitude by sequential concentrations.</p></sec></sec><sec id="sec3dot3-molecules-30-03584"><title>3.3. Molecular Docking</title><p>Molecular modeling studies were performed using Gnina 1.3 [<xref rid="B42-molecules-30-03584" ref-type="bibr">42</xref>] software, using S1R&#8217;s co-crystallized structure (PDB: 5HK2). Briefly, hydrogens and charges were added, and then ligands were separated and used as a reference to generate the searching box, with 4 &#197; added around this region. Binding poses were analyzed for their binding mode and assessed in comparison with the crystallized analog with the UCSF ChimeraX software, version 1.6.1.</p></sec></sec><sec sec-type="conclusions" id="sec4-molecules-30-03584"><title>4. Conclusions</title><p>Central nervous system (CNS) disorders remain among the most critical and challenging therapeutic areas of modern medicine. Accumulating preclinical evidence underscores the promise of selective sigma-1 receptor (S1R) agonists as effective treatments. Building upon our previous demonstration of compound <bold>1</bold> as a safe and efficacious S1R ligand for multiple sclerosis, this study reports the rational pharmacomodulation of this reference scaffold, leading to the design and characterization of six novel derivatives <bold>2</bold>&#8211;<bold>7</bold>.</p><p>Notably, compound <bold>2</bold>&#8212;a simple amide-inverted analog of compound <bold>1</bold>&#8212;exhibited a fivefold increase in S1R affinity, S2R/S1R selectivity, and toxicity index, highlighting the impact of subtle structural modifications. Although some moderate off-target affinity toward CNS receptors was observed at 10 &#181;M, compound <bold>2</bold> displayed an overall improved pharmacological profile relative to the reference compound <bold>1</bold>.</p><p>In terms of ADME properties, compound <bold>2</bold> demonstrated comparable bioavailability parameters to compound <bold>1</bold>, with slightly enhanced permeability and a modest increase in plasma protein binding. The most significant advancement lies in its markedly improved cardiac safety profile, with an IC<sub>50</sub> (hERG)/<italic toggle="yes">Ki</italic> (&#963;<sub>1</sub>) ratio exceeding that of compound <bold>1</bold> by nearly sevenfold.</p></sec><sec id="sec5-molecules-30-03584"><title>5. Patents</title><p>The compounds described in this manuscript have been patented [<xref rid="B43-molecules-30-03584" ref-type="bibr">43</xref>].</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to gratefully acknowledge Paul-Emmanuel Larchanch&#233; for the preparation of the SI file and the Region Hauts-de-France (France), the Minist&#232;re de la Jeunesse, de l&#8217;Education Nationale et de la Recherche (MJENR), and the Fonds Europ&#233;ens de D&#233;veloppement R&#233;gional (FEDER) for funds allowed for the 300 MHz NMR facilities.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-molecules-30-03584"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/molecules30173584/s1">https://www.mdpi.com/article/10.3390/molecules30173584/s1</uri>, Figure S1: LC-MS and NMR spectra of compounds <bold>2</bold>&#8211;<bold>7</bold>; Figure S2: Displacement related to S1R binding; Figure S3: Displacement related to S2R binding.</p><supplementary-material id="molecules-30-03584-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-03584-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, P.C., B.O., P.V. and P.M.; methodology, P.C., B.O., P.V. and P.M.; software, M.L.; validation, S.R., R.B., M.D.-M. and A.B.; formal analysis, S.R., R.B., M.D.-M. and A.B.; investigation, S.R., R.B., M.D.-M. and A.B.; data curation, S.R., R.B., M.D.-M. and A.B.; writing&#8212;original draft preparation, P.C., B.O. and P.M.; writing&#8212;review and editing, P.C., B.O. and P.M. visualization, P.C., B.O. and P.M.; supervision, P.C., B.O., P.V. and P.M.; project administration, B.O., P.V. and P.M.; funding acquisition, B.O., P.V. and P.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article/<xref rid="app1-molecules-30-03584" ref-type="app">Supplementary Materials</xref>. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-molecules-30-03584"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name></person-group><article-title>Mitochondria-Associated Membranes: A Key Point of Neurodegenerative Diseases</article-title><source>CNS Neurosci. Ther.</source><year>2025</year><volume>31</volume><fpage>e70378</fpage><pub-id pub-id-type="doi">10.1111/cns.70378</pub-id><pub-id pub-id-type="pmid">40406921</pub-id><pub-id pub-id-type="pmcid">PMC12099310</pub-id></element-citation></ref><ref id="B2-molecules-30-03584"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>MAM-mediated mitophagy and endoplasmic reticulum stress: The hidden regulators of ischemic stroke</article-title><source>Front. Cell. Neurosci.</source><year>2024</year><volume>18</volume><elocation-id>1470144</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2024.1470144</pub-id><pub-id pub-id-type="pmid">39640236</pub-id><pub-id pub-id-type="pmcid">PMC11617170</pub-id></element-citation></ref><ref id="B3-molecules-30-03584"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>K.</given-names></name></person-group><article-title>Mitochondria and Endoplasmic Reticulum Contact Site as a Regulator of Proteastatic Stress Responses in Neurodegenerative Diseases</article-title><source>BioEssays</source><year>2025</year><volume>47</volume><elocation-id>e70016</elocation-id><pub-id pub-id-type="doi">10.1002/bies.70016</pub-id><pub-id pub-id-type="pmid">40320859</pub-id><pub-id pub-id-type="pmcid">PMC12183774</pub-id></element-citation></ref><ref id="B4-molecules-30-03584"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delprat</surname><given-names>B.</given-names></name><name name-style="western"><surname>Crouzier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Maurice</surname><given-names>T.</given-names></name></person-group><article-title>At the Crossing of ER Stress and MAMs: A Key Role of Sigma-1 Receptor ?</article-title><source>Adv. Exp. Med. Biol.</source><year>2020</year><volume>1131</volume><fpage>699</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">31646531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-030-12457-1_28</pub-id></element-citation></ref><ref id="B5-molecules-30-03584"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marlar</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Thitilertdecha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ruckvongacheep</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Brimson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tencomnao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brimson</surname><given-names>J.M.</given-names></name></person-group><article-title>Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental disorders</article-title><source>CNS Drugs</source><year>2023</year><volume>37</volume><fpage>399</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1007/s40263-023-01007-6</pub-id><pub-id pub-id-type="pmid">37166702</pub-id><pub-id pub-id-type="pmcid">PMC10173947</pub-id></element-citation></ref><ref id="B6-molecules-30-03584"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fattakhov</surname><given-names>N.</given-names></name><name name-style="western"><surname>Toborek</surname><given-names>M.</given-names></name></person-group><article-title>Sigma-1 receptor signaling: A Potential therapeutic approach for ischemic stroke</article-title><source>J. Cereb. Blood Flow Metab.</source><year>2024</year><volume>44</volume><fpage>1430</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1177/0271678X241281547</pub-id><pub-id pub-id-type="pmid">39246093</pub-id><pub-id pub-id-type="pmcid">PMC11571975</pub-id></element-citation></ref><ref id="B7-molecules-30-03584"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>N.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wold</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>X.C.</given-names></name></person-group><article-title>Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><fpage>15187</fpage><lpage>15217</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01192</pub-id><pub-id pub-id-type="pmid">33111525</pub-id></element-citation></ref><ref id="B8-molecules-30-03584"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease drug development pipeline: 2024</article-title><source>Alzheimers Dement.</source><year>2024</year><volume>10</volume><fpage>e12465</fpage><pub-id pub-id-type="doi">10.1002/trc2.12465</pub-id><pub-id pub-id-type="pmcid">PMC11040692</pub-id><pub-id pub-id-type="pmid">38659717</pub-id></element-citation></ref><ref id="B9-molecules-30-03584"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macfarlane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grimmer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>K.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grunfeld</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mander</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brodtmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brew</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Blarcamesine for the treatment of Early Alzheimer&#8217;d Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial</article-title><source>J. Prev. Alzheimers Dis.</source><year>2025</year><volume>12</volume><fpage>100016</fpage><pub-id pub-id-type="doi">10.1016/j.tjpad.2024.100016</pub-id><pub-id pub-id-type="pmid">39800452</pub-id><pub-id pub-id-type="pmcid">PMC12184016</pub-id></element-citation></ref><ref id="B10-molecules-30-03584"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cenci</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Skovgard</surname><given-names>K.</given-names></name><name name-style="western"><surname>Odin</surname><given-names>P.</given-names></name></person-group><article-title>Non-dopaminergic approaches to the treatment of motor complications in Parkinson&#8217;s disease</article-title><source>Neuropharmacology</source><year>2022</year><volume>210</volume><fpage>109027</fpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2022.109027</pub-id><pub-id pub-id-type="pmid">35292330</pub-id></element-citation></ref><ref id="B11-molecules-30-03584"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van de Roovaart</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Veenstra</surname><given-names>T.D.</given-names></name></person-group><article-title>Huntington&#8217;s Disease Drug Development: A Phase 3 Pipeline Analysis</article-title><source>Pharmaceuticals</source><year>2023</year><volume>16</volume><elocation-id>1513</elocation-id><pub-id pub-id-type="doi">10.3390/ph16111513</pub-id><pub-id pub-id-type="pmid">38004378</pub-id><pub-id pub-id-type="pmcid">PMC10674993</pub-id></element-citation></ref><ref id="B12-molecules-30-03584"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cazenave-Gassiot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Charton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Girault-Mizzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gilleron</surname><given-names>P.</given-names></name><name name-style="western"><surname>Debreu-Fontaine</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sergheraert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Melnyk</surname><given-names>P.</given-names></name></person-group><article-title>Synthesis and pharmacological evaluation of Tic-Hydantoin derivatives as selective &#963;1 ligands. Part 2</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2005</year><volume>15</volume><fpage>4828</fpage><lpage>4832</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2005.07.039</pub-id><pub-id pub-id-type="pmid">16140009</pub-id></element-citation></ref><ref id="B13-molecules-30-03584"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venna</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Deplancke</surname><given-names>D.</given-names></name><name name-style="western"><surname>Melnyk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bordet</surname><given-names>R.</given-names></name></person-group><article-title>Neuroprotective and antidepressant-like effects of LC 03/55, a novel sigma-1 receptor ligand</article-title><source>Fundam. Clin. Pharmacol.</source><year>2008</year><volume>22</volume><fpage>1</fpage></element-citation></ref><ref id="B14-molecules-30-03584"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oxombre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lee-Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Duhamel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Toussaint</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giroux</surname><given-names>M.</given-names></name><name name-style="western"><surname>Donnier-Mar&#233;chal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carato</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lefranc</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zephir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Prin</surname><given-names>L.</given-names></name><etal/></person-group><article-title>High affinity sigma-1 receptor agonist reduces clinical and pathological signs of experimental auto-immune encephalomyelitis</article-title><source>Br. J. Pharmacol.</source><year>2015</year><volume>172</volume><fpage>1769</fpage><lpage>1782</lpage><pub-id pub-id-type="doi">10.1111/bph.13037</pub-id><pub-id pub-id-type="pmid">25521311</pub-id><pub-id pub-id-type="pmcid">PMC4376455</pub-id></element-citation></ref><ref id="B15-molecules-30-03584"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donnier-Mar&#233;chal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carato</surname><given-names>P.</given-names></name><name name-style="western"><surname>Larchanch&#233;</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Ravez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boulahjar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barczyk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oxombre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vermersch</surname><given-names>P.</given-names></name><name name-style="western"><surname>Melnyk</surname><given-names>P.</given-names></name></person-group><article-title>Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 ligands</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>138</volume><fpage>964</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.07.014</pub-id><pub-id pub-id-type="pmid">28756263</pub-id></element-citation></ref><ref id="B16-molecules-30-03584"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oxombre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Madouri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Journ&#233;</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Ravez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Woitrain</surname><given-names>E.</given-names></name><name name-style="western"><surname>Odou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Duhal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ninni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montaigne</surname><given-names>D.</given-names></name><name name-style="western"><surname>Delhem</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Safe and efficient sigma1 ligand: A potential drug candidate for Multiple Sclerosis</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>11893</elocation-id><pub-id pub-id-type="doi">10.3390/ijms231911893</pub-id><pub-id pub-id-type="pmid">36233193</pub-id><pub-id pub-id-type="pmcid">PMC9569529</pub-id></element-citation></ref><ref id="B17-molecules-30-03584"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganapathy</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Seth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leibach</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Ganapathy</surname><given-names>V.</given-names></name></person-group><article-title>Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1999</year><volume>289</volume><fpage>251</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(24)38131-5</pub-id><pub-id pub-id-type="pmid">10087012</pub-id></element-citation></ref><ref id="B18-molecules-30-03584"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gurpinar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koehl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Manglik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kruse</surname><given-names>A.C.</given-names></name></person-group><article-title>Crystal structure of the human &#963;1 receptor</article-title><source>Nature</source><year>2016</year><volume>532</volume><fpage>527</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/nature17391</pub-id><pub-id pub-id-type="pmid">27042935</pub-id><pub-id pub-id-type="pmcid">PMC5550834</pub-id></element-citation></ref><ref id="B19-molecules-30-03584"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Poul</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hisada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mizuguchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dupriez</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Burgeon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Detheux</surname><given-names>M.</given-names></name></person-group><article-title>Adaptation of Aequorin Functional Assay to High Throughput Screening</article-title><source>J. Biomol. Screen.</source><year>2002</year><volume>7</volume><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1089/108705702753520341</pub-id><pub-id pub-id-type="pmid">11897056</pub-id></element-citation></ref><ref id="B20-molecules-30-03584"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Degorce</surname><given-names>F.</given-names></name><name name-style="western"><surname>Card</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trinquet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Knapik</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>B.</given-names></name></person-group><article-title>HTRF: A Technology Tailored for Drug Discovery&#8212;A Review of Theoretical Aspects and Recent Applications</article-title><source>Curr. Chem. Genom.</source><year>2009</year><volume>3</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.2174/1875397300903010022</pub-id><pub-id pub-id-type="pmcid">PMC2802762</pub-id><pub-id pub-id-type="pmid">20161833</pub-id></element-citation></ref><ref id="B21-molecules-30-03584"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kolodin</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Zuck</surname><given-names>P.</given-names></name><name name-style="western"><surname>Peltier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mandala</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ota</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ozaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Inglese</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A fully automated [35S]GTPgammaS scintillation proximity assay for the high-throughput screening of Gi-linked G protein-coupled receptors</article-title><source>Assay Drug Dev. Technol.</source><year>2003</year><volume>1</volume><fpage>261</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1089/15406580360545071</pub-id><pub-id pub-id-type="pmid">15090191</pub-id></element-citation></ref><ref id="B22-molecules-30-03584"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Su</surname><given-names>T.-P.</given-names></name></person-group><article-title>Sigma-1 Receptor Chaperones at the ER-Mitochondrion Interface Regulate Ca<sup>2+</sup> Signaling and Cell Survival</article-title><source>Cell</source><year>2007</year><volume>131</volume><fpage>596</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.08.036</pub-id><pub-id pub-id-type="pmid">17981125</pub-id></element-citation></ref><ref id="B23-molecules-30-03584"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurice</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hiramatsu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kameyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nabeshima</surname><given-names>T.</given-names></name></person-group><article-title>Behavioral Evidence for a Modulating Role of Sigma Ligands in Memory Processes. I. Attenuation of Dizocilpine (MK-801)-Induced Amnesia</article-title><source>Brain Res.</source><year>1994</year><volume>647</volume><fpage>44</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(94)91397-8</pub-id><pub-id pub-id-type="pmid">8069704</pub-id></element-citation></ref><ref id="B24-molecules-30-03584"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Lupo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Crouzier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bencomo-Mart&#237;nez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meunier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morilleau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Delprat</surname><given-names>B.</given-names></name><name name-style="western"><surname>Carrazana</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Men&#233;ndez Soto Del Valle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maurice</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Tanty</surname><given-names>C.</given-names></name></person-group><article-title>Amylovis-201 is a dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the sigma-1 chaperone protein</article-title><source>Acta Pharm. Sin. B</source><year>2024</year><volume>14</volume><fpage>4345</fpage><lpage>4359</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.06.013</pub-id><pub-id pub-id-type="pmid">39525570</pub-id><pub-id pub-id-type="pmcid">PMC11544189</pub-id></element-citation></ref><ref id="B25-molecules-30-03584"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Lombardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dominy</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Feeney</surname><given-names>P.J.</given-names></name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title><source>Adv. Drug Deliv. Rev.</source><year>2001</year><volume>46</volume><fpage>3</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(00)00129-0</pub-id><pub-id pub-id-type="pmid">11259830</pub-id></element-citation></ref><ref id="B26-molecules-30-03584"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hidalgo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Raub</surname><given-names>T.</given-names></name><name name-style="western"><surname>Borchardt</surname><given-names>R.</given-names></name></person-group><article-title>Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability</article-title><source>Gastroenterology</source><year>1989</year><volume>96</volume><fpage>736</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(89)80072-1</pub-id><pub-id pub-id-type="pmid">2914637</pub-id></element-citation></ref><ref id="B27-molecules-30-03584"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banker</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.A.</given-names></name></person-group><article-title>Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding</article-title><source>J. Pharm. Sci.</source><year>2003</year><volume>92</volume><fpage>967</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1002/jps.10332</pub-id><pub-id pub-id-type="pmid">12712416</pub-id></element-citation></ref><ref id="B28-molecules-30-03584"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dierks</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Stams</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Cornelius</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ball</surname><given-names>S.E.</given-names></name></person-group><article-title>A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry</article-title><source>Drug Metab. Dispos.</source><year>2001</year><volume>29</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">11124225</pub-id></element-citation></ref><ref id="B29-molecules-30-03584"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kido</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Giacomini</surname><given-names>K.M.</given-names></name></person-group><article-title>Profiling of a Prescription Drug Library for Potential Renal Drug&#8211;Drug Interactions Mediated by the Organic Cation Transporter 2</article-title><source>J. Med. Chem.</source><year>2011</year><volume>54</volume><fpage>4548</fpage><lpage>4558</lpage><pub-id pub-id-type="doi">10.1021/jm2001629</pub-id><pub-id pub-id-type="pmid">21599003</pub-id><pub-id pub-id-type="pmcid">PMC3257218</pub-id></element-citation></ref><ref id="B30-molecules-30-03584"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craddock</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Love</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>P.A.</given-names></name></person-group><article-title>Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter</article-title><source>Am. J. Physiol. Liver Physiol.</source><year>1998</year><volume>274</volume><fpage>G157</fpage><lpage>G169</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.1998.274.1.G157</pub-id><pub-id pub-id-type="pmid">9458785</pub-id></element-citation></ref><ref id="B31-molecules-30-03584"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paturi</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Kwatra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ananthula</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>A.K.</given-names></name></person-group><article-title>Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3)</article-title><source>Int. J. Pharm.</source><year>2010</year><volume>384</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2009.09.037</pub-id><pub-id pub-id-type="pmid">19782742</pub-id><pub-id pub-id-type="pmcid">PMC2830792</pub-id></element-citation></ref><ref id="B32-molecules-30-03584"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>O.K.</given-names></name><name name-style="western"><surname>Topp</surname><given-names>E.</given-names></name><name name-style="western"><surname>Makagiansar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Siahaan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yazdanian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Audus</surname><given-names>K.L.</given-names></name></person-group><article-title>Multidrug resistance-associated protein-1 functional activity in Calu-3 cells</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2001</year><volume>298</volume><fpage>1199</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(24)29493-3</pub-id><pub-id pub-id-type="pmid">11504821</pub-id></element-citation></ref><ref id="B33-molecules-30-03584"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Norinder</surname><given-names>U.</given-names></name><name name-style="western"><surname>Bergstr&#246;m</surname><given-names>C.A.S.</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name></person-group><article-title>Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs</article-title><source>Pharm. Res.</source><year>2009</year><volume>26</volume><fpage>1816</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.1007/s11095-009-9896-0</pub-id><pub-id pub-id-type="pmid">19421845</pub-id></element-citation></ref><ref id="B34-molecules-30-03584"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Theile</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ketabi-Kiyanvash</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lindenmaier</surname><given-names>H.</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>W.E.</given-names></name></person-group><article-title>Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside.; nucleotide.; and non-nucleoside reverse transcriptase inhibitors</article-title><source>Drug Metab. Dispos.</source><year>2007</year><volume>35</volume><fpage>340</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1124/dmd.106.012765</pub-id><pub-id pub-id-type="pmid">17172311</pub-id></element-citation></ref><ref id="B35-molecules-30-03584"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Leake</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cvetkovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roden</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Nadeau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walubo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>G.R.</given-names></name></person-group><article-title>Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1999</year><volume>291</volume><fpage>1204</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(24)35228-0</pub-id><pub-id pub-id-type="pmid">10565843</pub-id></element-citation></ref><ref id="B36-molecules-30-03584"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cihlar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>E.S.</given-names></name></person-group><article-title>Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1</article-title><source>Anal. Biochem.</source><year>2000</year><volume>283</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1006/abio.2000.4633</pub-id><pub-id pub-id-type="pmid">10929807</pub-id></element-citation></ref><ref id="B37-molecules-30-03584"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Obaidat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chaguturu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hagenbuch</surname><given-names>B.</given-names></name></person-group><article-title>Development of a Cell-Based High-Throughput Assay to Screen for Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3</article-title><source>Curr. Chem. Genom.</source><year>2010</year><volume>4</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2174/1875397301004010001</pub-id><pub-id pub-id-type="pmcid">PMC2864424</pub-id><pub-id pub-id-type="pmid">20448812</pub-id></element-citation></ref><ref id="B38-molecules-30-03584"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polli</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wring</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Humphreys</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>L.O.</given-names></name><name name-style="western"><surname>Serabjit-Singh</surname><given-names>C.S.</given-names></name></person-group><article-title>Rational use of in vitro P-glycoprotein assays in drug discovery</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2001</year><volume>299</volume><fpage>620</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(24)29270-3</pub-id><pub-id pub-id-type="pmid">11602674</pub-id></element-citation></ref><ref id="B39-molecules-30-03584"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Prusoff</surname><given-names>W.H.</given-names></name></person-group><article-title>Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</article-title><source>Biochem. Pharmacol.</source><year>1973</year><volume>22</volume><fpage>3099</fpage><lpage>3108</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(73)90196-2</pub-id><pub-id pub-id-type="pmid">4202581</pub-id></element-citation></ref><ref id="B40-molecules-30-03584"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fahmi</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Kish</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boldt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Obach</surname><given-names>R.S.</given-names></name></person-group><article-title>Cytochrome P450 3A4 mRNA Is a More Reliable Marker than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing Enzymes</article-title><source>Drug Metab. Dispos.</source><year>2010</year><volume>38</volume><fpage>1605</fpage><lpage>1611</lpage><pub-id pub-id-type="doi">10.1124/dmd.110.033126</pub-id><pub-id pub-id-type="pmid">20566695</pub-id></element-citation></ref><ref id="B41-molecules-30-03584"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathes</surname><given-names>C.</given-names></name></person-group><article-title>QPatch: The past, present and future of automated patch clamp</article-title><source>Expert Opin. Ther. Targets</source><year>2006</year><volume>10</volume><fpage>319</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1517/14728222.10.2.319</pub-id><pub-id pub-id-type="pmid">16548779</pub-id></element-citation></ref><ref id="B42-molecules-30-03584"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNutt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koes</surname><given-names>D.R.</given-names></name></person-group><article-title>GNINA 1.3: The next increment in molecular docking with deep learning (Primary application citation)</article-title><source>J. Cheminformatics</source><year>2025</year><volume>17</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s13321-025-00973-x</pub-id><pub-id pub-id-type="pmcid">PMC11874439</pub-id><pub-id pub-id-type="pmid">40025560</pub-id></element-citation></ref><ref id="B43-molecules-30-03584"><label>43.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Melnyk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vermersch</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carato</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vanteghem-Oxombre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zephir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Donnier-Mar&#233;chal</surname><given-names>M.</given-names></name></person-group><article-title>Compounds, Pharmaceutical Composition and Their Use in Treating Neurodegenerative Diseases</article-title><source>Patent</source><patent>WO/2015/193255</patent><day>16</day><month>June</month><year>2014</year></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Scheme and Tables</title><fig position="float" id="molecules-30-03584-f001" orientation="portrait"><label>Figure 1</label><caption><p>Design of compounds <bold>2</bold>&#8211;<bold>7</bold> and the previous lead compound <bold>1</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03584-g001.jpg"/></fig><fig position="float" id="molecules-30-03584-sch001" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03584-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Synthesis of compounds <bold>2</bold>&#8211;<bold>7</bold>. Reagents and conditions: 3-chloropropionyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, 12 h, 0 &#176;C to rt, 60&#8211;79%; (b): <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-benzylmethylamine, rt, 12 h, 37&#8211;80%.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03584-sch001.jpg"/></fig><fig position="float" id="molecules-30-03584-f002" orientation="portrait"><label>Figure 2</label><caption><p>Docking of compounds <bold>1</bold> and <bold>2</bold> in the binding site of S1R (PDB entry: 5HK2). Compound <bold>1</bold> is drawn in blue; compound <bold>2</bold> in red.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03584-g002.jpg"/></fig><fig position="float" id="molecules-30-03584-f003" orientation="portrait"><label>Figure 3</label><caption><p>In vitro evaluation of agonist activity of compounds <bold>2</bold>, <bold>3,</bold> and <bold>6</bold>: The effects of compounds <bold>2</bold>, <bold>3</bold>, and <bold>6</bold> at 1 and 10 &#181;M on the S1R-BiP association after 30 min of incubation were analyzed by co-immunoprecipitation using an anti-S1R antibody (red). BiP levels were quantified by ELISA. PRE-084 (white) and NE-100 (black) served as the reference agonist and antagonist, respectively (10 &#181;M). Agonist activity was confirmed by its blockade with NE-100 (black hatching). The absence of antagonist activity was validated by co-treatment with PRE-084 (white hatching). Data represent the mean &#177; SEM from <italic toggle="yes">n</italic> = 6 per condition. Statistical significance was assessed using Dunnett&#8217;s test: *** <italic toggle="yes">p</italic> &lt; 0.0001, * <italic toggle="yes">p</italic> &lt; 0.05 vs. untreated control; ### <italic toggle="yes">p</italic> &lt; 0.0001, # <italic toggle="yes">p</italic> &lt; 0.05 for NE-100 blockade.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03584-g003.jpg"/></fig><table-wrap position="float" id="molecules-30-03584-t001" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03584-t001_Table 1</object-id><label>Table 1</label><caption><p>Evaluation of S1R- and S2R-binding affinities and cytotoxicity of compounds <bold>2</bold>&#8211;<bold>7</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="7" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-03584-i001.jpg"/>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cpd.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S1R<break/>(<italic toggle="yes">K<sub>i</sub></italic> nM) <sup>a</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S2R<break/>(<italic toggle="yes">K<sub>i</sub></italic> nM) <sup>a</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">K<sub>i</sub></italic> (S2R)/<break/><italic toggle="yes">K<sub>i</sub></italic> (S1R)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SY5Y <break/>% Cytotox <sup>b</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> (SY5Y) <sup>c</sup>/<break/><italic toggle="yes">K<sub>i</sub></italic> (S1R)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">4-Cl</td><td align="center" valign="top" rowspan="1" colspan="1">3.2</td><td align="center" valign="top" rowspan="1" colspan="1">190</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">&gt;31,250</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">3-Cl</td><td align="center" valign="top" rowspan="1" colspan="1">0.6</td><td align="center" valign="top" rowspan="1" colspan="1">200</td><td align="center" valign="top" rowspan="1" colspan="1">317</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">&gt;166,666</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">4-Cl</td><td align="center" valign="top" rowspan="1" colspan="1">1.7</td><td align="center" valign="top" rowspan="1" colspan="1">410</td><td align="center" valign="top" rowspan="1" colspan="1">241</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">&gt;58,823</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">3-Br</td><td align="center" valign="top" rowspan="1" colspan="1">&gt;200</td><td align="center" valign="top" rowspan="1" colspan="1">&gt;200</td><td align="center" valign="top" rowspan="1" colspan="1">nd</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">nd</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>5</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">2,4-diCl</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td><td align="center" valign="top" rowspan="1" colspan="1">120</td><td align="center" valign="top" rowspan="1" colspan="1">52</td><td align="center" valign="top" rowspan="1" colspan="1">37</td><td align="center" valign="top" rowspan="1" colspan="1">&gt;43,478</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">4-CN</td><td align="center" valign="top" rowspan="1" colspan="1">5.6</td><td align="center" valign="top" rowspan="1" colspan="1">1800</td><td align="center" valign="top" rowspan="1" colspan="1">331</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">&gt;17,857</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">4-NO<sub>2</sub></td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">110</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">6500</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">59</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;909</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Mean <italic toggle="yes">K<sub>i</sub></italic> values for 2&#8211;3 independent experiments are shown with less than 10% deviation. <sup>b</sup> Percentage of cell death after 24 h treatment at the dose of 100 &#181;M (duplicate). <sup>c</sup> IC<sub>50</sub> was considered &gt; 100 &#181;M. nd: not determined.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-30-03584-t002" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03584-t002_Table 2</object-id><label>Table 2</label><caption><p>Selectivity study of compounds <bold>2</bold>, <bold>3</bold>, <bold>6</bold>, and <bold>7</bold>.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
<bold>Cpd</bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>5-HT<sub>1A</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>5-HT<sub>1B</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>5-HT<sub>2A</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>5-HT<sub>2B</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>5-HT<sub>2C</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>5-HT<sub>3</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>5-HT<sub>4e</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>5-HT<sub>5a</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>5-HT<sub>6</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>5-HT<sub>7</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>A<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>A<sub>2A</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>A<sub>3</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>&#946;<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>&#946;<sub>2</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>&#945;<sub>1a</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>&#945;<sub>1b</sub></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1"><bold>1</bold> [<xref rid="B19-molecules-30-03584" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:red" rowspan="1" colspan="1">92</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">73</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">72</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">68</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">64</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">70</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">76</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">72</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">76</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:red" rowspan="1" colspan="1">88</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">65</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:red" rowspan="1" colspan="1">93</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">56</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">52</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">80</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">61</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Cpd</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>&#945;<sub>2a</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>&#945;<sub>2b</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>&#945;<sub>2c</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>AT<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>CB<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>CB<sub>2</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>CCK<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>CCK<sub>2</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>CGRP</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>CXCR<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>CysLT<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>D<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>D<sub>2</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>D<sub>3</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>D<sub>4.4</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Eta</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>ETb</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1"><bold>1</bold> [<xref rid="B19-molecules-30-03584" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">61</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">59</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">64</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">54</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:red" rowspan="1" colspan="1">84</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Cpd</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>GHS-R</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>H<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>H<sub>2</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>H<sub>3</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>MTL</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>M<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>M<sub>2</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>M<sub>3</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>M<sub>4</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>M<sub>5</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>ORL<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>NK<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>NK<sub>2</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>NPY<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>NMDA</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[b]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1"><bold>1</bold> [<xref rid="B19-molecules-30-03584" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Cpd</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>&#948;</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>&#954;</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>&#181;</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>SST4</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Uroll</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>V<sub>1a</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>V<sub>1b</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>VPAC<sub>1</sub></bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>B1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[a]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[b]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1"><bold>1</bold> [<xref rid="B19-molecules-30-03584" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#92D050" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>[a]: Agonist activity at 10 &#181;M in duplicate. [b]: Antagonist activity at 10 &#181;M in duplicate. For the agonist activity, data are expressed as the percentage of the activity of the reference agonist. For the antagonist activity, data are expressed as the percentage of inhibition of the reference agonist activity. In green, 0&#8211;50%; in white, 51&#8211;80%; in red, 81&#8211;100%. Numerical values are indicated over 51%.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-30-03584-t003" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03584-t003_Table 3</object-id><label>Table 3</label><caption><p>Preliminary ADME study of compounds <bold>2</bold> and <bold>6</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1 [<xref rid="B16-molecules-30-03584" ref-type="bibr">16</xref>]</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">6</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Solubility</bold> (&#181;M)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PBS<sub>pH7.4</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">185</td><td align="center" valign="middle" rowspan="1" colspan="1">167</td><td align="center" valign="middle" rowspan="1" colspan="1">190</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SGF</td><td align="center" valign="middle" rowspan="1" colspan="1">193</td><td align="center" valign="middle" rowspan="1" colspan="1">186</td><td align="center" valign="middle" rowspan="1" colspan="1">178</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">188</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">181</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">190</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Permeability</bold> (&#215;10<sup>&#8722;6</sup> cm/s) (10 &#181;M)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">A/B <sub>pH7.4/7.4</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">29.1</td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">49.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">B/A <sub>pH7.4/7.4</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">66.1</td><td align="center" valign="middle" rowspan="1" colspan="1">67.4</td><td align="center" valign="middle" rowspan="1" colspan="1">60.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e-ratio</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Plasma protein binding</bold> (10 &#181;M) %</td><td align="center" valign="middle" rowspan="1" colspan="1">94</td><td align="center" valign="middle" rowspan="1" colspan="1">98</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mouse plasma t<sub>1/2</sub> (h)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;48</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Metabolic stability</bold> (10 &#181;M)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Human liver microsome</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Intrinsic clearance (&#181;L/min/pmol)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;115.5</td><td align="center" valign="middle" rowspan="1" colspan="1">135.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;115.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Half-life t<sub>1/2</sub> (min)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;60</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>CYP inhibition</bold> (% at 10 &#181;M)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1A</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">23.3</td><td align="center" valign="middle" rowspan="1" colspan="1">13.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2B6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;4.3</td><td align="center" valign="middle" rowspan="1" colspan="1">16.9</td><td align="center" valign="middle" rowspan="1" colspan="1">17.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2C8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;9.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;16.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;12.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2C9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;7.2</td><td align="center" valign="middle" rowspan="1" colspan="1">13.1</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2C19</td><td align="center" valign="middle" rowspan="1" colspan="1">36.2</td><td align="center" valign="middle" rowspan="1" colspan="1">43.9</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2D6</td><td align="center" valign="middle" rowspan="1" colspan="1">95.1</td><td align="center" valign="middle" rowspan="1" colspan="1">80.5</td><td align="center" valign="middle" rowspan="1" colspan="1">87.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Drug transport inhibition</bold> (% at 10 &#181;M)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">ABC family</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">P-gp</td><td align="center" valign="middle" rowspan="1" colspan="1">10.6</td><td align="center" valign="middle" rowspan="1" colspan="1">4.7</td><td align="center" valign="middle" rowspan="1" colspan="1">4.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BCRP</td><td align="center" valign="middle" rowspan="1" colspan="1">8.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;5.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MRP1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MRP2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;18.6</td><td align="center" valign="middle" rowspan="1" colspan="1">5.6</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MRP3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">SLC family</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OAT1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;9.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;23.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;25.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OAT3</td><td align="center" valign="middle" rowspan="1" colspan="1">34.3</td><td align="center" valign="middle" rowspan="1" colspan="1">33.3</td><td align="center" valign="middle" rowspan="1" colspan="1">27.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OATP1B1</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OCT1</td><td align="center" valign="middle" rowspan="1" colspan="1">41.2</td><td align="center" valign="middle" rowspan="1" colspan="1">19.9</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OCT2</td><td align="center" valign="middle" rowspan="1" colspan="1">49.4</td><td align="center" valign="middle" rowspan="1" colspan="1">54.1</td><td align="center" valign="middle" rowspan="1" colspan="1">59.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ABST</td><td align="center" valign="middle" rowspan="1" colspan="1">5.3</td><td align="center" valign="middle" rowspan="1" colspan="1">21.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;8.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NTCP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;1.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;12.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>hERG inhibition</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IC<sub>50</sub> (&#181;M)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">6.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> (hERG)/<italic toggle="yes">Ki</italic> (&#963;<sub>1</sub>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">312</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,333</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">143</td></tr></tbody></table><table-wrap-foot><fn><p>Results are expressed as means (<italic toggle="yes">n</italic> = 2).</p></fn></table-wrap-foot></table-wrap></sec></back></article></pmc-articleset>